BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA, Agarwal A, Bhatt M, Khatib R, Riva JJ, Zhang Y, Guyatt G. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018;2:3257-91. [PMID: 30482765 DOI: 10.1182/bloodadvances.2018024893] [Cited by in Crossref: 246] [Cited by in F6Publishing: 255] [Article Influence: 61.5] [Reference Citation Analysis]
Number Citing Articles
1 İslam MM, Ademoğlu E, Uygun C, Delipoyraz M, Satıcı MO, Aksel G, Eroğlu SE, Özdemir S. Comparison of the effects of different treatment protocols on mortality in patients presenting with an INR≥10 due to warfarin-associated over-anticoagulation. Afr J Emerg Med 2023;13:8-14. [PMID: 36700167 DOI: 10.1016/j.afjem.2022.12.001] [Reference Citation Analysis]
2 Djulbegovic B, Hozo I, Lizarraga D, Thomas J, Barbee M, Shah N, Rubeor T, Dale J, Reiser J, Guyatt G. Evaluation of a fast-and-frugal clinical decision algorithm ('pathways') on clinical outcomes in hospitalised patients with COVID-19 treated with anticoagulants. J Eval Clin Pract 2023;29:3-12. [PMID: 36229950 DOI: 10.1111/jep.13780] [Reference Citation Analysis]
3 Giamello JD, Pisano A, Corsini F, Melchio R, Bertolaccini L, Lupia E, Lauria G. Use of anticoagulation reversal therapy in the emergency department: a single-center real-life retrospective study. World J Emerg Med 2023;14:56-8. [PMID: 36713347 DOI: 10.5847/wjem.j.1920-8642.2023.004] [Reference Citation Analysis]
4 Puchstein D, Kork F, Schöchl H, Rayatdoost F, Grottke O. 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis. Thromb Haemost 2023;123:40-53. [PMID: 36626899 DOI: 10.1055/s-0042-1758653] [Reference Citation Analysis]
5 Wee B, Lui B, Lai J, Khattak Z, Kwok A, Donarelli C, Ho P, Lim HY. Management of venous thromboembolism in morbidly obese patients: a 10-year review. J Thromb Thrombolysis 2022. [DOI: 10.1007/s11239-022-02738-x] [Reference Citation Analysis]
6 Fleischer MI, Röhrig N, Raker VK, Springer J, Becker D, Ritz S, Bros M, Stege H, Haist M, Grabbe S, Haub J, Becker C, Reyda S, Disse J, Schmidt T, Mahnke K, Weiler H, Ruf W, Steinbrink K. Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation. J Thromb Haemost 2022;20:2823-36. [PMID: 36161697 DOI: 10.1111/jth.15894] [Reference Citation Analysis]
7 Busko AM, Solano JJ, Clayton LM, Hughes PG, Paley RJ, Shih RD, Alter SM. The Role of Thromboelastography in Identifying Coagulopathy Among Geriatric Traumatic Brain Injury Patients. Cureus 2022;14:e32818. [PMID: 36694515 DOI: 10.7759/cureus.32818] [Reference Citation Analysis]
8 Wu S, Lv M, Chen J, Jiang S, Chen M, Fang Z, Zeng Z, Qian J, Xu W, Guan C, Zhang J. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis. Support Care Cancer 2022;30:10407-20. [PMID: 36318341 DOI: 10.1007/s00520-022-07433-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yuen HLA, Fang W, Tran H, Chunilal SD. Cannula provoked upper extremity superficial vein thrombophlebitis: are we overtreating? Intern Med J 2022;52:1995-7. [PMID: 36326238 DOI: 10.1111/imj.15951] [Reference Citation Analysis]
10 Padua H, Cahill AM, Chewning R, Himes EA, Kukreja K, Kumar R, Marshalleck F, Monroe E, Patel S, Samelson-Jones BJ, Shaikh R. Appendix to the Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions: Pediatric Considerations. J Vasc Interv Radiol 2022:S1051-0443(22)01062-4. [PMID: 35842024 DOI: 10.1016/j.jvir.2022.07.006] [Reference Citation Analysis]
11 Sherwin E, Schaefer M, Huffmyer M, Naseman K, Davis GA, Schadler A, Fraley S, Smith B. Evaluation of a pharmacist-led drive-up anticoagulation clinic during the coronavirus 2019 pandemic. Journal of the American Pharmacists Association 2022. [DOI: 10.1016/j.japh.2022.09.024] [Reference Citation Analysis]
12 Poenou G, Dumitru Dumitru T, Lafaie L, Mismetti V, Ayoub E, Duvillard C, Accassat S, Mismetti P, Heestermans M, Bertoletti L. Pulmonary Embolism in the Cancer Associated Thrombosis Landscape. JCM 2022;11:5650. [DOI: 10.3390/jcm11195650] [Reference Citation Analysis]
13 Duffett L. Deep Venous Thrombosis. Ann Intern Med 2022. [PMID: 36095313 DOI: 10.7326/AITC202209200] [Reference Citation Analysis]
14 Salter B, Crowther M. A Historical Perspective on the Reversal of Anticoagulants. Semin Thromb Hemost 2022. [PMID: 36055273 DOI: 10.1055/s-0042-1753485] [Reference Citation Analysis]
15 O'brien JW, Rogers M, Gallagher M, Rockall T. Management of massive gastrointestinal haemorrhage. Surgery (Oxford) 2022;40:582-592. [DOI: 10.1016/j.mpsur.2022.05.020] [Reference Citation Analysis]
16 Blackburn M. Four-factor prothrombin complex concentrate administration after expanding intracranial hemorrhage status post administration of andexanet alfa. Am J Emerg Med 2022:S0735-6757(22)00543-5. [PMID: 36038405 DOI: 10.1016/j.ajem.2022.08.041] [Reference Citation Analysis]
17 Martens KL, Dekker SE, Crowe M, DeLoughery TG, Shatzel JJ. Challenging clinical scenarios for therapeutic anticoagulation: A practical approach. Thromb Res 2022;218:72-82. [PMID: 36027629 DOI: 10.1016/j.thromres.2022.08.015] [Reference Citation Analysis]
18 Holbrook AM, Vidug K, Yoo L, Troyan S, Schulman S, Douketis J, Thabane L, Giilck S, Koubaesh Y, Hyland S, Keshavjee K, Ho J, Tarride JE, Ahmed A, Talman M, Leonard B, Ahmed K, Refaei M, Siegal DM. Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): protocol for a pilot randomised controlled trial. Pilot Feasibility Stud 2022;8:166. [PMID: 35918731 DOI: 10.1186/s40814-022-01130-z] [Reference Citation Analysis]
19 Yogasundaram H, Dover DC, Hawkins NM, McAlister FA, Goodman SG, Ezekowitz J, Kaul P, Sandhu RK. Trends in Uptake and Adherence to Oral Anticoagulation for Patients With Incident Atrial Fibrillation at High Stroke Risk Across Health Care Settings. J Am Heart Assoc 2022;:e024868. [PMID: 35876419 DOI: 10.1161/JAHA.121.024868] [Reference Citation Analysis]
20 Sharma AE, Khoong EC, Rivadeneira N, Sierra M, Fang MC, Gupta N, Pramanik R, Tran H, Whitezell T, Fontil V, Lee SY, Sarkar U. Warfarin Monitoring in Safety-Net Health Systems: Analysis by Race/Ethnicity and Language Preference. J Gen Intern Med 2022;37:2703-10. [PMID: 34993871 DOI: 10.1007/s11606-021-07283-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Sperry JD, Rose AE, Williams E, Dierks MR, Medow JE. Emergent Reversal of Antithrombotics and Treatment of Life-Threatening Bleeding from Coagulopathies: A Clinical Review. J Emerg Med 2022:S0736-4679(22)00324-9. [PMID: 35918220 DOI: 10.1016/j.jemermed.2022.05.011] [Reference Citation Analysis]
22 Barletta JF, Erstad BL. Dosing Medications for Coagulopathy Reversal in Patients with Extreme Obesity. J Emerg Med 2022:S0736-4679(22)00307-9. [PMID: 35906122 DOI: 10.1016/j.jemermed.2022.04.036] [Reference Citation Analysis]
23 Di Maggio R, Giuliano A, Renda D, Calvaruso G, Raso S, Pitrolo L, Carroccio A, Maggio A. A Patient with Sickle Cell Disease and Recurrent Venous Thromboembolism after Renal Transplantation. Thalassemia Reports 2022;12:85-89. [DOI: 10.3390/thalassrep12030013] [Reference Citation Analysis]
24 Garay OU, Guiñazú G, Adamczuk YP, Duboscq C. Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina. Pharmacoecon Open 2022. [PMID: 35835938 DOI: 10.1007/s41669-022-00352-4] [Reference Citation Analysis]
25 Kahn SR, de Wit K. Pulmonary Embolism. N Engl J Med 2022;387:45-57. [PMID: 35793208 DOI: 10.1056/NEJMcp2116489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Gorog DA, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, Konstantinidis SV, Lane DA, Marin F, Oldgren J, Potpara T, Roldan V, Rubboli A, Sibbing D, Tse HF, Vilahur G, Lip GYH. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022. [PMID: 35793691 DOI: 10.1055/s-0042-1750385] [Reference Citation Analysis]
27 Metze M, Platz M, Pfrepper C, Petros S. Gerinnungsdiagnostik im klinischen Alltag – Teil 2. Innere Medizin 2022;63:736-750. [DOI: 10.1007/s00108-022-01335-7] [Reference Citation Analysis]
28 Paik J. Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism. Paediatr Drugs 2022;24:423-31. [PMID: 35699915 DOI: 10.1007/s40272-022-00516-z] [Reference Citation Analysis]
29 Fang MC, Go AS, Prasad PA, Zhou HX, Parks AL, Fan D, Portugal C, Sung SH, Reynolds K. Health-related quali ty of life associated with warfarin and direct oral anticoagulants in venous thromboembolism. Thromb Res 2022;216:97-102. [PMID: 35779378 DOI: 10.1016/j.thromres.2022.06.008] [Reference Citation Analysis]
30 Tritschler T, Cusano E, Langlois N, Mathieu ME, Hutton B, Shea BJ, Shorr R, Skeith L, Duffett L, Cowley L, Ng S, Dubois S, West C, Tugwell P, Le Gal G. Identification of outcomes in clinical studies of interventions for venous thromboembolism in non-pregnant adults: A scoping review. J Thromb Haemost 2022. [PMID: 35717670 DOI: 10.1111/jth.15787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Yamashita Y, Morimoto T, Klok FA, Barco S, Nishimoto Y, Kato T, Ono K, Kimura T; COMMAND VTE Registry Investigators. Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry. J Thromb Thrombolysis 2022. [PMID: 35713842 DOI: 10.1007/s11239-022-02665-x] [Reference Citation Analysis]
32 Jaspers TCC, Keyany A, Maat B, Meijer K, van den Bemt PMLA, Khorsand N. Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey. Eur J Clin Pharmacol 2022. [PMID: 35715569 DOI: 10.1007/s00228-022-03344-9] [Reference Citation Analysis]
33 Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B, Coleman CI. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care 2022;26:180. [PMID: 35710578 DOI: 10.1186/s13054-022-04043-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Oliveira LB, Mwangi VI, Sartim MA, Delafiori J, Sales GM, de Oliveira AN, Busanello ENB, Val FFAE, Xavier MS, Costa FT, Baía-da-Silva DC, Sampaio VS, de Lacerda MVG, Monteiro WM, Catharino RR, de Melo GC. Metabolomic Profiling of Plasma Reveals Differential Disease Severity Markers in COVID-19 Patients. Front Microbiol 2022;13:844283. [PMID: 35572676 DOI: 10.3389/fmicb.2022.844283] [Reference Citation Analysis]
35 Bradshaw PG, Keegan S, Foertsch M, Yang GL, Ngwenya LB, Srinivasan V. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series. J Thromb Thrombolysis 2022. [PMID: 35507109 DOI: 10.1007/s11239-022-02658-w] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Ibarra F, Cruz M, Ford M, Wu M. Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies. Pharmacy 2022;10:50. [DOI: 10.3390/pharmacy10030050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Mohamed M, Musa M, Fadul A, Abdallah I, Najim M, Saeed A. Treatment Failure of Cerebral Venous Thrombosis With Rivaroxaban: A Case Report and Narrative Review. Cureus. [DOI: 10.7759/cureus.23778] [Reference Citation Analysis]
38 Tadesse TA, Abiye AA, Endale S, Yadeta D, Chelkeba L, Fenta TG. Challenges of Anticoagulation Management Service and Need of Establishing Pharmacist-Led Anticoagulation Clinic in Tertiary Care Teaching Hospital, Ethiopia: A Qualitative Study. JMDH 2022;Volume 15:743-54. [DOI: 10.2147/jmdh.s359558] [Reference Citation Analysis]
39 Saunders J, Vazquez SR, Jones AE, Fearon JM, Wegener P, Wilson A, Witt DM. Feasibility study of the Fearon Algorithm in anticoagulation service guided warfarin management. Thrombosis Update 2022. [DOI: 10.1016/j.tru.2022.100105] [Reference Citation Analysis]
40 Pfrepper C, Metze M, Weise M, Koch E, Siegemund R, Siegemund A, Petros S. Body weight adapted tinzaparin treatment in patients with obesity. Thrombosis Research 2022. [DOI: 10.1016/j.thromres.2022.04.011] [Reference Citation Analysis]
41 Gorog DA, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, Konstantinidis SV, Lane DA, Marin F, Oldgren J, Potpara T, Roldan V, Rubboli A, Sibbing D, Tse HF, Vilahur G, Lip GYH. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace 2022:euac020. [PMID: 35323922 DOI: 10.1093/europace/euac020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 ICM-VTE General Delegates. Recommendations from the ICM-VTE: General. J Bone Joint Surg Am 2022;104:4-162. [PMID: 35315607 DOI: 10.2106/JBJS.21.01531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
43 Cohen AT, Lewis M, Connor A, Connolly SJ, Yue P, Curnutte J, Alikhan R, Maccallum P, Tan J, Green L. Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding. JACEP Open 2022;3. [DOI: 10.1002/emp2.12655] [Reference Citation Analysis]
44 Jiménez-fonseca P, Gallardo E, Arranz Arija F, Blanco JM, Callejo A, Lavin DC, Costa Rivas M, Mosquera J, Rodrigo A, Sánchez Morillas R, Vares Gonzaléz M, Muñoz A, Carmona-bayonas A. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.02.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Albin CSW, Barra ME. Reversal of Selected Antithrombotics. The Acute Neurology Survival Guide 2022. [DOI: 10.1007/978-3-030-75732-8_38] [Reference Citation Analysis]
46 Asrani R, Bahou WF, Department of Medicine/Hematology, Stony Brook University, Stony Brook, NY, USA, Department of Medicine/Hematology, Stony Brook University, Stony Brook, NY, USA. COVID Coagulopathy and Thrombosis: A Systematic Review. Oncology & Haematology 2022;18:78. [DOI: 10.17925/ohr.2022.18.1.78] [Reference Citation Analysis]
47 Carballo Álvarez F, Albillos Martínez A, Llamas Silero P, Orive Calzada A, Redondo-cerezo E, Rodríguez de Santiago E, Crespo García J. Consensus document of the Sociedad Española de Patología Digestiva on massive nonvariceal gastrointestinal bleeding and direct-acting oral anticoagulants. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8920/2022] [Reference Citation Analysis]
48 Gibbs L, Moulton J, Tichenor V. Venous Thromboembolism. Family Medicine 2022. [DOI: 10.1007/978-3-030-54441-6_88] [Reference Citation Analysis]
49 Kircher CE, Adeoye O. Prehospital and Emergency Department Care of the Patient With Acute Stroke. Stroke 2022. [DOI: 10.1016/b978-0-323-69424-7.00052-1] [Reference Citation Analysis]
50 Oyakawa T, Fukumitsu M, Ebihara A, Shiga T. Relevance of Non-Bridging Therapy with Heparin during Temporary Interruption of Direct Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism. Annals of Vascular Diseases. [DOI: 10.3400/avd.oa.22-00005] [Reference Citation Analysis]
51 Yang Q, Zyck SA, Gould G, Gorji R, Li F. Management of Patients on Anticoagulants and Antiplatelets in Neurosurgery. Transfusion Practice in Clinical Neurosciences 2022. [DOI: 10.1007/978-981-19-0954-2_40] [Reference Citation Analysis]
52 Na B, Park S. Perioperative Management of Morbidly Obese Patients during Major Abdominal Surgery. Ann Clin Nutr Metab 2021;13:26-33. [DOI: 10.15747/acnm.2021.13.2.26] [Reference Citation Analysis]
53 Lin YS, Lin MS, Wu VC, Chen YL, Chang JJ, Chu PH, Lip GYH, Chen MC. Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients. Front Cardiovasc Med 2021;8:775564. [PMID: 34938791 DOI: 10.3389/fcvm.2021.775564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Hofer S, Schlimp CJ, Casu S, Grouzi E. Management of Coagulopathy in Bleeding Patients. J Clin Med 2021;11:1. [PMID: 35011742 DOI: 10.3390/jcm11010001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? Hematology Am Soc Hematol Educ Program 2021;2021:521-8. [PMID: 34889442 DOI: 10.1182/hematology.2021000287] [Reference Citation Analysis]
56 Zhou X, Ding T, Wang S, Wen L. In vivo real-time monitoring of anti-factor Xa level using a microdialysis-coupled microfluidic device. Talanta Open 2021;4:100059. [DOI: 10.1016/j.talo.2021.100059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Wiercioch W, Nieuwlaat R, Zhang Y, Alonso-Coello P, Dahm P, Iorio A, Manja V, Mustafa RA, Neumann I, Ortel TL, Rochwerg B, Santesso N, Vesely SK, Akl EA, Schünemann HJ. New methods facilitated the process of prioritizing questions and health outcomes in guideline development. J Clin Epidemiol 2021:S0895-4356(21)00389-9. [PMID: 34843861 DOI: 10.1016/j.jclinepi.2021.11.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Panahi L, Udeani G, Horseman M, Weston J, Samuel N, Joseph M, Mora A, Bazan D, Patel P. Anticoagulants in the Management of Pulmonary Embolism. Pulmonary Embolism [Working Title] 2021. [DOI: 10.5772/intechopen.100471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Willeford A, Leiman V, Noel ZR. Impact of a pharmacist‐to‐dose direct oral anticoagulant protocol on medication errors at an academic medical center. J Am Coll Clin Pharm 2021;4:1392-1400. [DOI: 10.1002/jac5.1503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Hill K, Sucha E, Rhodes E, Bota S, Hundemer GL, Clark EG, Canney M, Harel Z, Wang T, Carrier M, Wijeysundera HC, Knoll G, Sood MM. Amiodarone, verapamil, or diltiazem use with direct oral anticoagulants and the risk of hemorrhage in older adults. CJC Open 2021. [DOI: 10.1016/j.cjco.2021.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
61 Godon A, Tacquard CA, Mansour A, Garrigue D, Nguyen P, Lasne D, Testa S, Levy JH, Albaladejo P, Gruel Y, Susen S, Godier A, le Gihp P, Gfht L. Prévention du risque thromboembolique veineux et surveillance de l’hémostase chez les patients hospitalisés pour COVID-19 : propositions réactualisées (avril 2021). Groupe d’intérêt en hémostase périopératoire (GIHP) et groupe d’étude sur l’hémostase et la thrombose (GFHT). Anesthésie & Réanimation 2021;7:467-476. [DOI: 10.1016/j.anrea.2021.08.002] [Reference Citation Analysis]
62 Milling TJ, Refaai MA, Sengupta N. Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines. Dig Dis Sci 2021;66:3698-714. [PMID: 33403486 DOI: 10.1007/s10620-020-06728-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Davis SD, Chauv S, Hickman AW, Collingridge DS, Kjerengtroen S, Fontaine GV. High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage. Thromb Res 2021;208:112-6. [PMID: 34749042 DOI: 10.1016/j.thromres.2021.10.026] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Alsubaie NS, Al Rammah SM, Alshouimi RA, Alzahrani MY, Al Yami MS, Almutairi AR, Alfayez OM, Korayem GB, Almohammed OA. The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines. Thromb J 2021;19:76. [PMID: 34717653 DOI: 10.1186/s12959-021-00326-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Jones AE, Saunders J, Vazquez SR, Fagerlin A, Witt DM. A survey of current anticoagulation patient education practices and development. Thromb Res 2021;208:11-3. [PMID: 34673367 DOI: 10.1016/j.thromres.2021.10.003] [Reference Citation Analysis]
66 Navin SF, Nardolillo J, Stambaugh A, Young C, Nguyen P, Apodaca M. Pharmacist monitoring of direct oral anticoagulants for American Indians and Alaska Natives in the outpatient setting. J Am Pharm Assoc (2003) 2021:S1544-3191(21)00428-3. [PMID: 34728162 DOI: 10.1016/j.japh.2021.10.009] [Reference Citation Analysis]
67 Gong X, He Q, Yan J, Chen J, Chen X, Huang M, Li J, Chen P. A drug utilization study of oral anticoagulants in five representative cities of China between 2015 and 2019. J Clin Pharm Ther 2021. [PMID: 34592785 DOI: 10.1111/jcpt.13538] [Reference Citation Analysis]
68 Lecumberri R, Jiménez L, Ruiz-Artacho P, Nieto JA, Ruiz-Giménez N, Visonà A, Skride A, Moustafa F, Trujillo J, Monreal M; RIETE investigators . Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores. TH Open 2021;5:e319-28. [PMID: 34568742 DOI: 10.1055/s-0041-1729171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
69 Lotfi T, Hajizadeh A, Moja L, Akl EA, Piggott T, Kredo T, Langendam MW, Iorio A, Klugar M, Klugarová J, Neumann I, Wiercioch W, Leontiadis GI, Mbuagbaw L, Turgeon AF, Meerpohl J, Stevens A, Brozek J, Santesso N, Pottie K, Dewidar O, Flottorp SA, Karpusheff J, Saz-Parkinson Z, Rojas MX, Parmelli E, Chu DK, Tugwell P, Welch V, Avey MT, Brignardello-Petersen R, Mathew JL, Munn Z, Nieuwlaat R, Ford N, Qaseem A, Askie LM, Schünemann HJ. A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. J Clin Epidemiol 2021:S0895-4356(21)00314-0. [PMID: 34562579 DOI: 10.1016/j.jclinepi.2021.09.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Stevens VM, Trujillo TC, Kiser TH, MacLaren R, Reynolds PM, Mueller SW. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clin Appl Thromb Hemost 2021;27:10760296211039020. [PMID: 34541920 DOI: 10.1177/10760296211039020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
71 Abdoellakhan RA, Khorsand N, Ter Avest E, Lameijer H, Faber LM, Ypma PF, Nieuwenhuizen L, Veeger NJGM, Meijer K. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial. Ann Emerg Med 2022;79:20-30. [PMID: 34535300 DOI: 10.1016/j.annemergmed.2021.06.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
72 Little DHW, Sutradhar R, Cerasuolo JO, Perez R, Douketis J, Holbrook A, Paterson JM, Gomes T, Siegal DM. Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. CMAJ 2021;193:E304-9. [PMID: 33649169 DOI: 10.1503/cmaj.201433] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
73 Darlow J, Mould H. Thrombophilia testing in the era of direct oral anticoagulants. Clin Med (Lond) 2021;21:e487-91. [PMID: 34493545 DOI: 10.7861/clinmed.2020-1008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract 2021. [PMID: 34512214 DOI: 10.1016/j.nurpra.2021.08.026] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Smythe MA, Koerber JM, Hoffman JL, Mertz S, Fritsch K, Chehab F, Baalbaki N, Krishnan A. Outcomes of activated prothrombin complex concentrate for direct Xa inhibitor bleeding. Thromb Res 2021;206:142-4. [PMID: 34481221 DOI: 10.1016/j.thromres.2021.08.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Sánchez FL, Calvo RS, Hernández PV, Cortés RP. Enfermedad venosa aguda. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:2258-2269. [DOI: 10.1016/j.med.2021.08.002] [Reference Citation Analysis]
77 Wiethorn EE, Harrison S, Weeda ER, Bell CM. Effectiveness and Safety of Twice- Versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center. Ann Pharmacother 2021;:10600280211041380. [PMID: 34459268 DOI: 10.1177/10600280211041380] [Reference Citation Analysis]
78 Brazeale HS, Fuentes A, Adeola M. Analysis of Direct Oral Anticoagulant Therapy With Concomitant Use of Interacting Antiretroviral Agents. J Pharm Pract 2021;:8971900211034258. [PMID: 34392711 DOI: 10.1177/08971900211034258] [Reference Citation Analysis]
79 Neumann I, Izcovich A, Alexander KE, Castano J, Plovnick R, Kunkle R, Zhang Y, Aguilar R, Basantes GL, Casais P, Colorio CC, Guillermo Esposito MC, García Lázaro PP, Pereira J, Meillon-García LA, Rezende SM, Serrano JC, Tejerina Valle ML, Schünemann H. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context. Blood Adv 2021;5:3047-52. [PMID: 34374749 DOI: 10.1182/bloodadvances.2021004268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Neumann I, Izcovich A, Aguilar R, Basantes GL, Casais P, Colorio CC, Esposito MCG, Lázaro PPG, Meillon-García LA, Pereira J, Rezende SM, Serrano JC, Valle MLT, Vera F, Karzulovic L, Rada G, Schünemann H. ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America. Blood Adv 2021;5:3032-46. [PMID: 34374748 DOI: 10.1182/bloodadvances.2021004267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Benipal H, Holbrook A, Paterson JM, Douketis J, Foster G, Ma J, Thabane L. Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home. Thromb Res 2021;206:18-28. [PMID: 34391064 DOI: 10.1016/j.thromres.2021.07.016] [Reference Citation Analysis]
82 Atchinson PRA, Hatton CJ, Roginski MA, Backer ED, Long B, Lentz SA. The emergency department evaluation and management of massive hemoptysis. Am J Emerg Med 2021;50:148-55. [PMID: 34365064 DOI: 10.1016/j.ajem.2021.07.041] [Reference Citation Analysis]
83 Pearson LN, Johnson SA, Greene DN, Chambliss AB, Farnsworth CW, French D, Herman DS, Kavsak PA, Merrill AE, Lo SM, Lyon ME, SoRelle JA, Schmidt RL. Side-Effects of COVID-19 on Patient Care: An INR Story. J Appl Lab Med 2021;6:953-61. [PMID: 33760097 DOI: 10.1093/jalm/jfab025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Hitchcock ZR, Smith SD, Le LT, Lees LR, Brandt MD. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings. J Pharm Pract 2021;:8971900211026839. [PMID: 34231410 DOI: 10.1177/08971900211026839] [Reference Citation Analysis]
85 Dietrich SK, Mixon MA, Rech MA. Fixed-dose prothrombin complex concentrate for emergent warfarin reversal among patients with intracranial hemorrhage. Am J Emerg Med 2021;49:326-30. [PMID: 34224954 DOI: 10.1016/j.ajem.2021.06.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Godon A, Tacquard CA, Mansour A, Garrigue D, Nguyen P, Lasne D, Testa S, Levy JH, Albaladejo P, Gruel Y, Susen S, Godier A; Gihp, the GFHT. Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021): From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care (SFAR). Anaesth Crit Care Pain Med 2021;40:100919. [PMID: 34182166 DOI: 10.1016/j.accpm.2021.100919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
87 Liu X, Xie G, Li Y, Xiang D, Zhang Y, Chen X, Long J. Evaluation of the algorithm of Anticlot Assistant: an anticoagulant management system based on mobile health technology. Blood Coagul Fibrinolysis 2021;32:221-4. [PMID: 33443921 DOI: 10.1097/MBC.0000000000000997] [Reference Citation Analysis]
88 Rivera-Lebron B, Bauersachs R. Direct oral anticoagulants for the treatment of pulmonary embolism in patients with renal impairment. Thromb Res 2021;204:101-7. [PMID: 34167039 DOI: 10.1016/j.thromres.2021.06.011] [Reference Citation Analysis]
89 Vestal ML, Hodulik K, Mando-Vandrick J, James ML, Ortel TL, Fuller M, Notini M, Friedland M, Welsby IJ. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis 2021. [PMID: 34101050 DOI: 10.1007/s11239-021-02495-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
90 Hafer A, McCann L. Direct oral anticoagulant reversal: An update. Nursing 2021;51:54-64. [PMID: 34014879 DOI: 10.1097/01.NURSE.0000743104.69943.67] [Reference Citation Analysis]
91 Abelhad NI, Qiao W, Garg N, Rojas-Hernandez CM. Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer. Thromb J 2021;19:37. [PMID: 34074321 DOI: 10.1186/s12959-021-00292-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Patel P, Patel P, Bhatt M, Braun C, Begum H, Nieuwlaat R, Khatib R, Martins CC, Zhang Y, Etxeandia-Ikobaltzeta I, Varghese J, Alturkmani H, Bahaj W, Baig M, Kehar R, Mustafa A, Ponnapureddy R, Sethi A, Thomas M, Wooldridge D, Lim W, Bates SM, Lang E, Le Gal G, Haramati LB, Kline J, Righini M, Wiercioch W, Schünemann H, Mustafa RA. Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism. Blood Adv 2021;5:2237-44. [PMID: 33900385 DOI: 10.1182/bloodadvances.2020002398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Yan M, Kieser R, Wu CC, Qiao W, Rojas-Hernandez CM. Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients. Blood Adv 2021;5:1050-8. [PMID: 33599740 DOI: 10.1182/bloodadvances.2020003136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927-74. [PMID: 33570602 DOI: 10.1182/bloodadvances.2020003442] [Cited by in Crossref: 152] [Cited by in F6Publishing: 177] [Article Influence: 76.0] [Reference Citation Analysis]
95 Ibarra F Jr. Review of Prothrombin Complex Concentrates Use in Apixaban and Rivaroxaban Associated Intracranial Hemorrhages. J Pharm Pract 2021;:8971900211015059. [PMID: 34036837 DOI: 10.1177/08971900211015059] [Reference Citation Analysis]
96 Jaspers T, Shudofsky K, Huisman MV, Meijer K, Khorsand N. A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding. Res Pract Thromb Haemost 2021;5:e12518. [PMID: 34084991 DOI: 10.1002/rth2.12518] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
97 Etxeandia-Ikobaltzeta I, Zhang Y, Brundisini F, Florez ID, Wiercioch W, Nieuwlaat R, Begum H, Cuello CA, Roldan Y, Chen R, Ding C, Morgan RL, Riva JJ, Zhang Y, Charide R, Agarwal A, Balduzzi S, Morgano GP, Yepes-Nuñez JJ, Rehman Y, Neumann I, Schwab N, Baldeh T, Braun C, Rodríguez MF, Schünemann HJ. Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines. Blood Adv 2020;4:953-68. [PMID: 32150612 DOI: 10.1182/bloodadvances.2019000462] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
98 Izcovich A, Cuker A, Kunkle R, Neumann I, Panepinto J, Pai M, Seftel M, Cheung MC, Lottenberg R, Byrne M, Plovnick R, Terrell D, Holter-Chakrabarty JL, Djulbegovic B, Hicks LK, Wiercioch W, Nieuwlaat R, Schünemann HJ. A user guide to the American Society of Hematology clinical practice guidelines. Blood Adv 2020;4:2095-110. [PMID: 32396622 DOI: 10.1182/bloodadvances.2020001755] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
99 Wiercioch W, Nieuwlaat R, Akl EA, Kunkle R, Alexander KE, Cuker A, Rajasekhar A, Alonso-Coello P, Anderson DR, Bates SM, Cushman M, Dahm P, Guyatt G, Iorio A, Lim W, Lyman GH, Middeldorp S, Monagle P, Mustafa RA, Neumann I, Ortel TL, Rochwerg B, Santesso N, Vesely SK, Witt DM, Schünemann HJ. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Adv 2020;4:2351-65. [PMID: 32453843 DOI: 10.1182/bloodadvances.2020001768] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
100 Patel P, Patel P, Bhatt M, Braun C, Begum H, Nieuwlaat R, Khatib R, Martins CC, Zhang Y, Etxeandia-Ikobaltzeta I, Varghese J, Alturkmani H, Bahaj W, Baig M, Kehar R, Mustafa A, Ponnapureddy R, Sethi A, Thomas M, Wooldridge D, Lim W, Bates SM, Lang E, Le Gal G, Righini M, Wiercioch W, Schünemann HJ, Mustafa RA. Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis. Blood Adv 2020;4:2779-88. [PMID: 32569377 DOI: 10.1182/bloodadvances.2020001558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
101 Sarode R, Fukutake K, Yasaka M, Tortorici MA, Mangione A, Pfister M, Cuker A. Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2. Blood Adv 2020;4:4208-16. [PMID: 32898246 DOI: 10.1182/bloodadvances.2020002267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S, Thurston C, Vedantham S, Verhamme P, Witt DM, D Florez I, Izcovich A, Nieuwlaat R, Ross S, J Schünemann H, Wiercioch W, Zhang Y, Zhang Y. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020;4:4693-738. [PMID: 33007077 DOI: 10.1182/bloodadvances.2020001830] [Cited by in Crossref: 266] [Cited by in F6Publishing: 295] [Article Influence: 133.0] [Reference Citation Analysis]
103 Wiercioch W, Nieuwlaat R, Dahm P, Iorio A, Mustafa RA, Neumann I, Rochwerg B, Manja V, Alonso-Coello P, Ortel TL, Santesso N, Vesely SK, Akl EA, Schünemann HJ, Zakai N, Cuker A, Lim W, Monagle P, Kunkle R, Witt DM, Kahn SR, McLintock C, Rezende SM, Zakai NA. Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. J Clin Epidemiol 2021;138:115-27. [PMID: 33992716 DOI: 10.1016/j.jclinepi.2021.04.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Sukumar S, Cabero M, Tiu S, Fang MC, Kogan SC, Schwartz JB. Anti-factor Xa activity assays of direct-acting oral anticoagulants during clinical care: An observational study. Res Pract Thromb Haemost 2021;5:e12528. [PMID: 34013157 DOI: 10.1002/rth2.12528] [Reference Citation Analysis]
105 Riva JJ, Bhatt M, Brunarski DJ, Busse JW, Martins CC, Xie F, Schünemann HJ, Brozek JL. Guidelines that use the GRADE approach often fail to provide complete economic information for recommendations: A systematic survey. J Clin Epidemiol 2021;136:203-15. [PMID: 33984495 DOI: 10.1016/j.jclinepi.2021.04.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Mirza R, Nieuwlaat R, López-Núñez JJ, Barba R, Agarwal A, Font C, Ciammaichella M, Grandone E, Ikesaka R, Crowther M, Monreal M; RIETE Investigators. Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). Blood Adv 2020;4:2460-7. [PMID: 32497167 DOI: 10.1182/bloodadvances.2019001373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
107 Kanjee Z, McCann ML, Freed JA. Availability of Specific Direct Oral Anticoagulant Reversal Agents in US Hospitals. JAMA Netw Open 2021;4:e2110079. [PMID: 33988710 DOI: 10.1001/jamanetworkopen.2021.10079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Elsamadisi P, Cepeda MAG, Yankama T, Wong A, Tran Q, Eche IM. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal. Am J Cardiovasc Drugs 2021;21:355-61. [PMID: 33150496 DOI: 10.1007/s40256-020-00442-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
109 Myers DD Jr, Ning J, Lester P, Adili R, Hawley A, Durham L, Dunivant V, Reynolds G, Crego K, Sood S, Sigler R, Fogler WE, Magnani JL, Holinstat M, Wakefield T. E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. J Vasc Surg Venous Lymphat Disord 2021:S2213-333X(21)00195-5. [PMID: 33872819 DOI: 10.1016/j.jvsv.2020.12.086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
110 Zaninetti C, Thiele T. Anticoagulation in Patients with Platelet Disorders. Hamostaseologie 2021;41:112-9. [PMID: 33860519 DOI: 10.1055/a-1344-7279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Fang MC, Go AS, Prasad PA, Hsu JW, Fan D, Portugal C, Sung SH, Reynolds K. Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism. J Thromb Thrombolysis 2021. [PMID: 33834371 DOI: 10.1007/s11239-021-02437-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
112 Stolow E, Moreau C, Sayana H, Patel S. Management of Non-Variceal Upper GI Bleeding in the Geriatric Population: An Update. Curr Gastroenterol Rep 2021;23:5. [PMID: 33768344 DOI: 10.1007/s11894-021-00805-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Huang HK, Peng CC, Lin SM, Munir KM, Chang RH, Wu BB, Liu PP, Hsu JY, Loh CH, Tu YK. Fracture Risks in Patients Treated With Different Oral Anticoagulants: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2021;10:e019618. [PMID: 33759542 DOI: 10.1161/JAHA.120.019618] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
114 Becattini C, Di Nisio M, Franco L, Lee A, Agnelli G, Mandalà M. Treatment of venous thromboembolism in cancer patients: The dark side of the moon. Cancer Treat Rev 2021;96:102190. [PMID: 33812338 DOI: 10.1016/j.ctrv.2021.102190] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
115 Grach SL, Saliba AN, Costello BA. 40-Year-Old Man With Left Leg Swelling and Abdominal Pain. Mayo Clin Proc 2021;96:782-7. [PMID: 33673926 DOI: 10.1016/j.mayocp.2020.07.041] [Reference Citation Analysis]
116 Douxfils J, Adcock DM, Bates SM, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S, Gosselin RC. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost 2021;121:1008-20. [PMID: 33742436 DOI: 10.1055/a-1450-8178] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
117 Jones AE, Saunders J, Vazquez S, Fagerlin A, Witt DM. A survey of current anticoagulation patient education practices and development.. [DOI: 10.1101/2021.03.11.21252961] [Reference Citation Analysis]
118 McRae HL, Militello L, Refaai MA. Updates in Anticoagulation Therapy Monitoring. Biomedicines 2021;9:262. [PMID: 33800804 DOI: 10.3390/biomedicines9030262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
119 Akhter MS, Hamali HA, Mobarki AA, Rashid H, Oldenburg J, Biswas A. SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm. J Clin Med 2021;10:1064. [PMID: 33806540 DOI: 10.3390/jcm10051064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Rech MA, Masic D, Hammond DA. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding. West J Emerg Med 2021;22:163-9. [PMID: 33856296 DOI: 10.5811/westjem.2020.11.47931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Alhmoud E, Abdelsamad O, Soaly E, Enany RE, Elewa H. Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar. J Thromb Thrombolysis 2021;51:297-300. [PMID: 32621151 DOI: 10.1007/s11239-020-02206-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
122 Ahmed Mohamed S, El- Gohary G, Algahtani F, Alayoubi F, Abd El-aziz N. Hematological Findings in COVID-19 and Insights to Stem Cell Therapy: From Bench to Practice. J Skin Stem Cell 2021;7. [DOI: 10.5812/jssc.107133] [Reference Citation Analysis]
123 Cohen H, Efthymiou M, Devreese KMJ. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome. J Thromb Haemost 2021;19:892-908. [PMID: 33325604 DOI: 10.1111/jth.15217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
124 Karim S, Islam A, Rafiq S, Laher I. The COVID-19 Pandemic: Disproportionate Thrombotic Tendency and Management Recommendations. Trop Med Infect Dis 2021;6:26. [PMID: 33670475 DOI: 10.3390/tropicalmed6010026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
125 Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid D, Griffin DO, Kahn SR, Klok FA, Lee AI, Neumann I, Pai A, Pai M, Righini M, Sanfilippo KM, Siegal D, Skara M, Touri K, Akl EA, Bou Akl I, Boulos M, Brignardello-Petersen R, Charide R, Chan M, Dearness K, Darzi AJ, Kolb P, Colunga-Lozano LE, Mansour R, Morgano GP, Morsi RZ, Noori A, Piggott T, Qiu Y, Roldan Y, Schünemann F, Stevens A, Solo K, Ventresca M, Wiercioch W, Mustafa RA, Schünemann HJ. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021;5:872-88. [PMID: 33560401 DOI: 10.1182/bloodadvances.2020003763] [Cited by in Crossref: 212] [Cited by in F6Publishing: 228] [Article Influence: 106.0] [Reference Citation Analysis]
126 Stevens H, McFadyen J, Chan N. Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents. Semin Respir Crit Care Med 2021;42:218-32. [PMID: 33601429 DOI: 10.1055/s-0041-1723953] [Reference Citation Analysis]
127 Renner E, Barnes GD. Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar. J Am Coll Cardiol 2020;76:2142-54. [PMID: 33121722 DOI: 10.1016/j.jacc.2020.07.070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
128 Eljilany I, Elarref M, Shallik N, Elzouki AN, Mohammed A, Shoman B, Ibrahim S, Carr C, Al-Badriyeh D, Cavallari LH, Elewa H. Periprocedural Anticoagulation Management of Patients receiving Warfarin in Qatar: A Prospective Cohort Study. Curr Probl Cardiol 2021;46:100816. [PMID: 33721568 DOI: 10.1016/j.cpcardiol.2021.100816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VH. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology 2021;77:629-58. [DOI: 10.1016/j.jacc.2020.09.011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 34.0] [Reference Citation Analysis]
130 Lachant DJ, Bach C, Fe A, White RJ, Lachant NA. Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli. ERJ Open Res 2021;7:00554-2020. [PMID: 33569503 DOI: 10.1183/23120541.00554-2020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
131 Panahi L, Udeani G, Horseman M, Weston J, Samuel N, Joseph M, Mora A, Bazan D. Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina (Kaunas) 2021;57:110. [PMID: 33530544 DOI: 10.3390/medicina57020110] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
132 Hill K, Sucha E, Rhodes E, Carrier M, Garg AX, Harel Z, Hundemer GL, Clark EG, Knoll G, McArthur E, Sood MM. Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. JAMA Intern Med 2020;180:1052-60. [PMID: 32511684 DOI: 10.1001/jamainternmed.2020.1835] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
133 Xu J, Zhang Y, Nie G. Intelligent antithrombotic nanomedicines: Progress, opportunities, and challenges. View 2021;2:20200145. [DOI: 10.1002/viw.20200145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Ammar AA, Ammar MA, Owusu KA, Brown SC, Kaddouh F, Elsamadicy AA, Acosta JN, Falcone GJ. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage. Neurocrit Care 2021;35:255-61. [PMID: 33403588 DOI: 10.1007/s12028-020-01161-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
135 Gibson CM, Hall C, Davis S, Schillig JM. Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. J Thromb Thrombolysis 2021. [PMID: 33400099 DOI: 10.1007/s11239-020-02360-9] [Reference Citation Analysis]
136 Gibbs L, Moulton J, Tichenor V. Venous Thromboembolism. Family Medicine 2021. [DOI: 10.1007/978-1-4939-0779-3_88-3] [Reference Citation Analysis]
137 Olson SR, Samuelson Bannow BT. Anticoagulation and Antiplatelet Guidelines. Blood and Marrow Transplant Handbook 2021. [DOI: 10.1007/978-3-030-53626-8_13] [Reference Citation Analysis]
138 Dougherty S, Essop MR, Webb R, Price S, Wilson N. Complications of Rheumatic Heart Disease and Acute Emergencies. Acute Rheumatic Fever and Rheumatic Heart Disease 2021. [DOI: 10.1016/b978-0-323-63982-8.00016-7] [Reference Citation Analysis]
139 Moreno G, Carbonell R, Bodí M, Rodríguez A. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Medicina Intensiva (English Edition) 2021;45:42-55. [DOI: 10.1016/j.medine.2020.06.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Overvad TF, Skjøth F, Albertsen IE, Larsen TB, Søgaard M, Lip GYH. Should We Reintroduce Previous Venous Thromboembolism Into Decision-Making for Anticoagulation in Atrial Fibrillation? Am J Med 2021;134:67-75.e5. [PMID: 32634387 DOI: 10.1016/j.amjmed.2020.05.042] [Reference Citation Analysis]
141 Levy JH, Sniecinski RM. Coagulopathy and Bleeding Management for Aortic Dissection Surgery. Aortic Dissection and Acute Aortic Syndromes 2021. [DOI: 10.1007/978-3-030-66668-2_39] [Reference Citation Analysis]
142 Lee HS, Kim YR, Shin EJ, Jang HW, Jo YH, Cho YS, Kim JH, Lee J. Development of Warfarin Talk: A Messenger Chatbot for Patients Taking Warfarin. Korean J Clin Pharm 2020;30:243-249. [DOI: 10.24304/kjcp.2020.30.4.243] [Reference Citation Analysis]
143 Condeni MS, Basting AT, Costello PG, DePriest A, Eriksson EA, Evans H, Hertel K, Holder AL, Kester AN, Kowalski KR, Bell CM, McLean B, Reichert M, Santibañez M, Wieruszewski PM, Newsome AS. Major publications in the critical care pharmacotherapy literature: 2019. J Crit Care 2021;62:197-205. [PMID: 33422810 DOI: 10.1016/j.jcrc.2020.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Tritschler T, Langlois N, Hutton B, Shea BJ, Shorr R, Ng S, Dubois S, West C, Iorio A, Tugwell P, Le Gal G. Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults. BMJ Open 2020;10:e040122. [PMID: 33293309 DOI: 10.1136/bmjopen-2020-040122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 McGurgan IJ, Ziai WC, Werring DJ, Al-Shahi Salman R, Parry-Jones AR. Acute intracerebral haemorrhage: diagnosis and management. Pract Neurol 2020:practneurol-2020-002763. [PMID: 33288539 DOI: 10.1136/practneurol-2020-002763] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
146 Lipari L, Yang S, Milligan B, Blunck J. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate. The American Journal of Emergency Medicine 2020;38:2641-5. [DOI: 10.1016/j.ajem.2020.08.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
147 Jennings DL, Rimsans J, Connors JM. Prothrombin Complex Concentrate for Warfarin Reversal in Patients with Continuous-Flow Left Ventricular Assist Devices: A Narrative Review. ASAIO J. 2020;66:482-488. [PMID: 31192853 DOI: 10.1097/mat.0000000000001021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
148 Bawiskar N, Andhale A, Hulkoti V, Acharya S, Shukla S. Haematological Manifestations of Covid-19 and Emerging Immunohaematological Therapeutic Strategies. jemds 2020;9:3489-3494. [DOI: 10.14260/jemds/2020/763] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
149 Hafer A, Mccann L. Direct oral anticoagulant reversal. Nursing Critical Care 2020;15:18-29. [DOI: 10.1097/01.ccn.0000718332.38919.36] [Reference Citation Analysis]
150 Little DHW, Robertson T, Douketis J, Dionne JC, Holbrook A, Xenodemetropoulos T, Siegal DM. Management of antithrombotic therapy after gastrointestinal bleeding: A mixed methods study of health‐care providers. J Thromb Haemost 2021;19:153-60. [DOI: 10.1111/jth.15111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
151 Rhoney DH, Chester KW, Darsey DA. Optimal Dosage and Administration Practices for Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate. Clin Appl Thromb Hemost 2020;26:107602962094747. [DOI: 10.1177/1076029620947474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Bavalia R, Abdoellakhan R, Beenen LF, Brekelmans MPA, Olie RH, Ten Cate H, Huisman MV, Kruip M, Middeldorp S, Meijer K, Hutten BA, Coppens M. Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. Thromb Res 2020;196:404-9. [PMID: 33011638 DOI: 10.1016/j.thromres.2020.09.028] [Reference Citation Analysis]
153 Hornung P, Khairoun M, Dekker FW, Kaasjager KAH, Huisman A, Jakulj L, Bos WJW, Rosendaal FR, Verhaar MC, Ocak G. Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes. PLoS One 2020;15:e0239222. [PMID: 33001983 DOI: 10.1371/journal.pone.0239222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
154 Parlakpinar H, Gunata M. SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. Cell Biochem Funct 2021;39:10-28. [PMID: 32992409 DOI: 10.1002/cbf.3591] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
155 Benipal H, Holbrook A, Paterson JM, Douketis J, Foster G, Thabane L. Predictors of oral anticoagulant-associated adverse events in seniors transitioning from hospital to home: a retrospective cohort study protocol. BMJ Open 2020;10:e036537. [PMID: 32963065 DOI: 10.1136/bmjopen-2019-036537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
156 Liem RI, Lanzkron S, D Coates T, DeCastro L, Desai AA, Ataga KI, Cohen RT, Haynes J, Osunkwo I, Lebensburger JD, Lash JP, Wun T, Verhovsek M, Ontala E, Blaylark R, Alahdab F, Katabi A, Mustafa RA. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv 2019;3:3867-97. [PMID: 31794601 DOI: 10.1182/bloodadvances.2019000916] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 18.3] [Reference Citation Analysis]
157 Shah A, Donovan K, McHugh A, Pandey M, Aaron L, Bradbury CA, Stanworth SJ, Alikhan R, Von Kier S, Maher K, Curry N, Shapiro S, Rowland MJ, Thomas M, Mason R, Holland M, Holmes T, Ware M, Gurney S, McKechnie SR. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. Crit Care 2020;24:561. [PMID: 32948243 DOI: 10.1186/s13054-020-03260-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 24.7] [Reference Citation Analysis]
158 Sakr Y, Giovini M, Leone M, Pizzilli G, Kortgen A, Bauer M, Tonetti T, Duclos G, Zieleskiewicz L, Buschbeck S, Ranieri VM, Antonucci E. Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review. Ann Intensive Care 2020;10:124. [PMID: 32953201 DOI: 10.1186/s13613-020-00741-0] [Cited by in Crossref: 93] [Cited by in F6Publishing: 102] [Article Influence: 31.0] [Reference Citation Analysis]
159 Gunasekaran K, Rajasurya V, Devasahayam J, Singh Rahi M, Chandran A, Elango K, Talari G. A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants. J Clin Med 2020;9:E2984. [PMID: 32942757 DOI: 10.3390/jcm9092984] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
160 Rakhit S, Nordness MF, Lombardo SR, Cook M, Smith L, Patel MB. Management and Challenges of Severe Traumatic Brain Injury. Semin Respir Crit Care Med 2021;42:127-44. [PMID: 32916746 DOI: 10.1055/s-0040-1716493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
161 Milling TJ, Pollack CV. A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus? The American Journal of Emergency Medicine 2020;38:1890-903. [DOI: 10.1016/j.ajem.2020.05.086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
162 Owusu KA, Effendi MK, DeFilippo NA, Reardon DP, Ian Lee A. Andexanet Alfa: Considerations and Practical Applications. Crit Pathw Cardiol 2019;18:200-6. [PMID: 31725512 DOI: 10.1097/HPC.0000000000000190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. BMJ. 2020;370:m2177. [PMID: 32759284 DOI: 10.1136/bmj.m2177] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 15.3] [Reference Citation Analysis]
164 Kow CS, Sunter W, Bain A, Zaidi STR, Hasan SS. Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. Am J Cardiovasc Drugs 2020;20:301-9. [PMID: 32458370 DOI: 10.1007/s40256-020-00415-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
165 Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. A current review of COVID-19 for the cardiovascular specialist. Am Heart J 2020;226:29-44. [PMID: 32497913 DOI: 10.1016/j.ahj.2020.04.025] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 21.7] [Reference Citation Analysis]
166 Gök Metin Z. COVID-19 Hastalığının Fizyopatolojisi ve Holistik Hemşirelik Yaklaşımı. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi 2020. [DOI: 10.31125/hunhemsire.775658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
167 Hartmann S, Biliouris K, Lesko LJ, Nowak-Göttl U, Trame MN. Quantitative Systems Pharmacology Model-Based Predictions of Clinical Endpoints to Optimize Warfarin and Rivaroxaban Anti-Thrombosis Therapy. Front Pharmacol 2020;11:1041. [PMID: 32765265 DOI: 10.3389/fphar.2020.01041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
168 Papakonstantinou PE, Tsioufis C, Konstantinidis D, Iliakis P, Leontsinis I, Tousoulis D. Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non- Vitamin K Antagonists Oral Anticoagulants. CPD 2020;26:2692-702. [DOI: 10.2174/1381612826666200420150517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Fantoni C, Bertù L, Galliazzo S, Pola R, Pomero F, Porfidia A, Porreca E, Valeriani E, Ageno W. Follow-up management of patients receiving direct oral anticoagulants. Intern Emerg Med 2021;16:571-80. [PMID: 32661795 DOI: 10.1007/s11739-020-02433-w] [Reference Citation Analysis]
170 Talari G, Demertzis ZD, Summey RD, Gill B, Kaatz S. Perioperative management of anticoagulation. Hosp Pract (1995) 2020;48:231-40. [PMID: 32627607 DOI: 10.1080/21548331.2020.1792138] [Reference Citation Analysis]
171 Paquette M, Witt DM, Holbrook A, Skov J, Ansell J, Schünemann HJ, Wiercioch W, Nieuwlaat R. A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation. Blood Adv 2019;3:1638-46. [PMID: 31138592 DOI: 10.1182/bloodadvances.2019000067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
172 Robert-ebadi H, Righini M. The 2019 ESC guidelines on pulmonary embolism: some further insights. European Journal of Internal Medicine 2020;77:6-8. [DOI: 10.1016/j.ejim.2020.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Houghton DE, Casanegra AI, Peterson LG, Cochuyt J, Hodge DO, Vlazny D, McBane RD, Froehling D, Wysokinski WE. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. Am J Hematol 2020;95:817-23. [PMID: 32267011 DOI: 10.1002/ajh.25820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
174 Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol 2020;95:834-47. [PMID: 32282949 DOI: 10.1002/ajh.25829] [Cited by in Crossref: 936] [Cited by in F6Publishing: 1061] [Article Influence: 312.0] [Reference Citation Analysis]
175 Ergün Y, Altintaş Aykan D. Advers İlaç Reaksiyonlarına Yaklaşım. Arşiv Kaynak Tarama Dergisi 2020;29:97-107. [DOI: 10.17827/aktd.555013] [Reference Citation Analysis]
176 Machin N, Ragni MV. Hormones and thrombosis: risk across the reproductive years and beyond. Transl Res 2020;225:9-19. [PMID: 32599096 DOI: 10.1016/j.trsl.2020.06.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
177 Mcconachie SM, Hanni CM, Raub JN, Mohammad RA, Wilhelm SM. The Impact of Multiple Renal Estimates on Pharmacist Dosing Recommendations: A Randomized Trial. Ann Pharmacother 2021;55:25-35. [DOI: 10.1177/1060028020935447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
178 Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, Dager WE, Deitelzweig SB, Ellsworth S, Garcia D, Kaatz S, Minichiello T. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020;50:72-81. [PMID: 32440883 DOI: 10.1007/s11239-020-02138-z] [Cited by in Crossref: 273] [Cited by in F6Publishing: 237] [Article Influence: 91.0] [Reference Citation Analysis]
179 Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, Godier A, Testa S, Levy JH, Albaladejo P, Gruel Y; GIHP and GFHT. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care 2020;24:364. [PMID: 32560658 DOI: 10.1186/s13054-020-03000-7] [Cited by in Crossref: 91] [Cited by in F6Publishing: 96] [Article Influence: 30.3] [Reference Citation Analysis]
180 Tao DL, Olson SR, DeLoughery TG, Shatzel JJ. The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: A systematic review and meta-analysis. Eur J Haematol 2020;105:360-2. [PMID: 32441350 DOI: 10.1111/ejh.13453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
181 Moreno G, Carbonell R, Bodí M, Rodríguez A. [Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients]. Med Intensiva (Engl Ed) 2021;45:42-55. [PMID: 32646669 DOI: 10.1016/j.medin.2020.06.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
182 Orsi FA, De Paula EV, Santos FO, Teruchkin MM, Campêlo DHC, Mello TT, Chindamo MC, Macedo AVS, Rocha AT, Ramacciotti E, Nascimento ACK, Annichino-Bizzacchi J, Lourenco DM, Guerra JCC, Rezende SM, Cavalheiro Filho C. Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy. Hematol Transfus Cell Ther 2020;42:300-8. [PMID: 32565232 DOI: 10.1016/j.htct.2020.06.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
183 Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract (1995) 2020;48:169-79. [PMID: 32429774 DOI: 10.1080/21548331.2020.1772639] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
184 Kwenandar F, Japar KV, Damay V, Hariyanto TI, Tanaka M, Lugito NPH, Kurniawan A. Coronavirus disease 2019 and cardiovascular system: A narrative review. Int J Cardiol Heart Vasc. 2020;29:100557. [PMID: 32550259 DOI: 10.1016/j.ijcha.2020.100557] [Cited by in Crossref: 46] [Cited by in F6Publishing: 65] [Article Influence: 15.3] [Reference Citation Analysis]
185 Romano T, Rein L, Celebre G, Hardman J. Comparing therapy outcomes of patients before and after enrolling in an anticoagulation self‐testing program. J Am Coll Clin Pharm 2020;3:743-748. [DOI: 10.1002/jac5.1226] [Reference Citation Analysis]
186 Vizcaíno G, Weir Medina J, Vizcaíno Carruyo J. Revisión sistemática y metanálisis del tratamiento anticoagulante en la trombosis asociada al cáncer. Implicaciones en estudios de no inferioridad. Invest Clin 2020;61:165-180. [DOI: 10.22209/ic.v61n2a07] [Reference Citation Analysis]
187 Balbi GGM, Pacheco MS, Monticielo OA, Funke A, Danowski A, Santiago MB, Staub HL, Rêgo J, de Andrade DCO. Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). Adv Rheumatol 2020;60:29. [PMID: 32460902 DOI: 10.1186/s42358-020-00125-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
188 Mahajan K, Chandra KS. Cardiovascular comorbidities and complications associated with coronavirus disease 2019. Med J Armed Forces India 2020;76:253-60. [PMID: 32773926 DOI: 10.1016/j.mjafi.2020.05.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
189 Benz AP, Eikelboom JW. Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors. Circulation 2020;141:1690-2. [PMID: 32453664 DOI: 10.1161/CIRCULATIONAHA.120.046932] [Reference Citation Analysis]
190 Panos NG, Cook AM, John S, Jones GM, Kelly H, Choi RK, Kalaria N, Rosini JM, Jones M, Rehman M, Ross PM, Motley B, Delibert S, George BP, Andrews CM, Neyens RR, Martin R, Schomer KJ, Armahizer MJ, Pajoumand M, May CC, Smetana KS, Strohm T, Hamm C, Jakubowski L, Keegan SP, Srinivasan V, Burdick CJ, Martinez OJ, Bahrassa F, May ST, Sowers KA, Lin EI, Rohaley DJ, Mackey J, Wetmore LL, Frick C, Thatikunta M, Urben L, Ammar AA, Owusu KA, Nguyen K, Erdman MJ, Gilbert BW, Demott JM, Peksa GD, Tobias PE, Da Silva I, Mahmoud LN, Sheahan B, Gennaro AG, Pizzi MA, Brophy GM, Rivet DJ, Strein M, Arandela K, Hellerslia V, Caylor MM. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Circulation 2020;141:1681-9. [DOI: 10.1161/circulationaha.120.045769] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
191 Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, Dager WE, Deitelzweig SB, Ellsworth S, Garcia D, Kaatz S, Minichiello T. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020;50:72-81. [PMID: 32440883 DOI: 10.1007/s11239-020-02138-z] [Cited by in Crossref: 233] [Cited by in F6Publishing: 1] [Article Influence: 77.7] [Reference Citation Analysis]
192 Bikdeli B, Jiménez D, Muriel A, Barrios D, Ballaz A, Verhamme P, Monreal M; RIETE Investigators., Coordinator of the RIETE Registry: Manuel Monreal. RIETE Steering Committee Members:. Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi. Eur Respir J 2020;56:2000538. [PMID: 32430430 DOI: 10.1183/13993003.00538-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
193 Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost 2020;4:550-61. [PMID: 32548553 DOI: 10.1002/rth2.12359] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
194 Cuker A. Development and use of clinical practice guidelines on venous thromboembolism. Transl Res 2020;225:1-8. [PMID: 32434007 DOI: 10.1016/j.trsl.2020.05.002] [Reference Citation Analysis]
195 Zheng N, Han X, Peng L, Nie X, Wang J, Ma L, Zan X. Assessment of direct oral anticoagulants administered as potentially inappropriate medications to elderly inpatients. Int J Clin Pharm 2020;42:871-8. [PMID: 32405716 DOI: 10.1007/s11096-020-01051-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
196 Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol 2020;75:2352-71. [PMID: 32201335 DOI: 10.1016/j.jacc.2020.03.031] [Cited by in Crossref: 1148] [Cited by in F6Publishing: 1339] [Article Influence: 382.7] [Reference Citation Analysis]
197 Barra ME, Das AS, Hayes BD, Rosenthal ES, Rosovsky RP, Fuh L, Patel AB, Goldstein JN, Roberts RJ. Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages. J Thromb Haemost 2020;18:1637-47. [DOI: 10.1111/jth.14838] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 15.3] [Reference Citation Analysis]
198 Stevens VM, Trujillo T, Mueller SW, MacLaren R, Reynolds PM, Kiser TH. Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center. Clin Appl Thromb Hemost 2019;25:1076029619896619. [PMID: 31876159 DOI: 10.1177/1076029619896619] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
199 Klanderman RB, Bosboom JJ, Korsten H, Zeiler T, Musson REA, Veelo DP, Geerts BF, van Bruggen R, de Korte D, Vlaar APJ. Colloid osmotic pressure of contemporary and novel transfusion products. Vox Sang 2020;115:664-75. [PMID: 32378239 DOI: 10.1111/vox.12932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
200 Dean RE, Maniam G, Vo T. Rectus sheath hematoma following enoxaparin administration. Proc (Bayl Univ Med Cent) 2020;33:460-1. [PMID: 32675988 DOI: 10.1080/08998280.2020.1759336] [Reference Citation Analysis]
201 El Boussadani B, Benajiba C, Aajal A, Ait Brik A, Ammour O, El Hangouch J, Oussama O, Oussama B, Tahiri N, Raissuni Z. [COVID-19 pandemia: Impact on the cariovascular system. Data of 1st April 2020]. Ann Cardiol Angeiol (Paris) 2020;69:107-14. [PMID: 32303363 DOI: 10.1016/j.ancard.2020.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
202 Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:2950-73. [PMID: 32311448 DOI: 10.1016/j.jacc.2020.04.031] [Cited by in Crossref: 1757] [Cited by in F6Publishing: 1593] [Article Influence: 585.7] [Reference Citation Analysis]
203 Tait RC, Hung A, Gardner RS. Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method. Clin Appl Thromb Hemost 2019;25:1076029619890423. [PMID: 31773973 DOI: 10.1177/1076029619890423] [Reference Citation Analysis]
204 Wilsey HA, Bailey AM, Schadler A, Davis GA, Nestor M, Pandya K. Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study. J Intensive Care Med 2021;36:597-603. [PMID: 32242482 DOI: 10.1177/0885066620916706] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
205 Langer A, Connors JM. Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. Anesthesiology 2020;133:223-32. [PMID: 32217870 DOI: 10.1097/ALN.0000000000003268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
206 Owen Ng Tsai H. Pharmacological Review of Anticoagulants. Anticoagulation Drugs - the Current State of the Art 2020. [DOI: 10.5772/intechopen.88407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Lin A, Vazquez SR, Jones AE, Witt DM. Description of anti-Xa monitoring practices during low molecular weight heparin use. J Thromb Thrombolysis 2019;48:623-8. [PMID: 31317300 DOI: 10.1007/s11239-019-01920-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
208 Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. J Am Coll Cardiol 2019;73:1336-49. [PMID: 30898209 DOI: 10.1016/j.jacc.2019.01.017] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 26.3] [Reference Citation Analysis]
209 Peled H, Dau NQ. Prothrombin Complex Concentrate or Coagulation Factor Xa (Recombinant), Inactivated-zhzo. Chest 2019;155:1308. [PMID: 31174650 DOI: 10.1016/j.chest.2019.02.335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
210 Wang M, Holbrook A, Lee M, Liu J, Leenus A, Chen N, Mbuagbaw L, Thabane L. Barriers and facilitators to optimal oral anticoagulant management: a scoping review. J Thromb Thrombolysis 2020;50:697-714. [DOI: 10.1007/s11239-020-02056-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
211 Dager WE, Ansell J, Barnes GD, Burnett A, Deitelzweig S, Minichiello T, Triller D, Kaatz S. "Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy": Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance. Jt Comm J Qual Patient Saf 2020;46:173-80. [PMID: 32005512 DOI: 10.1016/j.jcjq.2019.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
212 Kaide CG, Gulseth MP. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. The Journal of Emergency Medicine 2020;58:217-33. [DOI: 10.1016/j.jemermed.2019.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
213 Ishaaya E, Tapson VF. Advances in the diagnosis of acute pulmonary embolism. F1000Res 2020;9:F1000 Faculty Rev-44. [PMID: 32047618 DOI: 10.12688/f1000research.21347.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
214 Xu K, Chan NC. The conundrum of resuming anticoagulant therapy after intracerebral bleeding: In whom, when, and how? Vasc Med 2020;25:60-2. [DOI: 10.1177/1358863x19897140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
215 Diener H, Albers B, Smalling RW, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany, Albers Clinical Evidence Consultancy, Winterswijk Woold, The Netherlands, McGovern Medical School at UTHealth, Memorial Hermann Heart and Vascular Institute, Houston, TX, USA. Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke. US Neurology 2020;16:54. [DOI: 10.17925/usn.2020.16.1.54] [Reference Citation Analysis]
216 Gibbs L, Moulton J, Tichenor V. Venous Thromboembolism. Family Medicine 2020. [DOI: 10.1007/978-1-4939-0779-3_88-2] [Reference Citation Analysis]
217 Green D. Treatment of thrombosis. The Heparins 2020. [DOI: 10.1016/b978-0-12-818781-4.00004-2] [Reference Citation Analysis]
218 Mori M, Ichiki Y, Kanayama M, Taira A, Shinohara S, Kuwata T, Imanishi N, Yoneda K, Kuroda K, Tanaka F. The impact of perioperative heparin bridging therapy in lung cancer surgery. Gen Thorac Cardiovasc Surg 2020;68:623-8. [PMID: 31848903 DOI: 10.1007/s11748-019-01276-3] [Reference Citation Analysis]
219 Fazili M, Stevens SM, Woller SC. Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance. Res Pract Thromb Haemost 2020;4:9-12. [PMID: 31989078 DOI: 10.1002/rth2.12287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
220 Feinstein DL, Nosal DG, Ramanathan S, Zhou J, Chen L, Hershow RC, van Breemen RB, Wright E, Hafner JW, Rubinstein I. Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. Clin Toxicol (Phila) 2020;58:716-24. [PMID: 31736367 DOI: 10.1080/15563650.2019.1687903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
221 Tosetto A, Testa S, Palareti G, Paoletti O, Nichele I, Catalano F, Morandini R, Di Paolo M, Tala M, Esteban P, Cora' F, Mannino S, Maroni A, Sessa M, Castaman G. The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study. Intern Emerg Med 2019;14:1307-15. [PMID: 31309520 DOI: 10.1007/s11739-019-02148-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
222 Peled H, Dau NQ, Lau H. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 2020;33:20-4. [DOI: 10.1007/s12028-019-00866-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
223 Paul JD, Cifu AS. Prevention and Management of Venous Thromboembolism. JAMA 2019;322:1602-3. [PMID: 31545338 DOI: 10.1001/jama.2019.13853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
224 Du W, Zhao X, Nunno A, Li Y, Gu Y. Risk factors for venous thromboembolism in individuals undergoing coronary artery bypass grafting. J Vasc Surg Venous Lymphat Disord 2020;8:551-7. [PMID: 31619374 DOI: 10.1016/j.jvsv.2019.06.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
225 Taradin GG, Ignatenko GA, Vatutin NT, Kanisheva IV. CURRENT VIEW ON ANTICOAGULANT AND THROMBOLYTIC TREATMENT OF ACUTE PULMONARY EMBOLISM. Arhivʺ vnutrennej mediciny 2019;9:348-366. [DOI: 10.20514/2226-6704-2019-9-5-348-366] [Reference Citation Analysis]
226 Mackenzie PD, Rogers M, Gallagher M, Rockall T. Management of massive gastrointestinal haemorrhage. Surgery (Oxford) 2019;37:565-575. [DOI: 10.1016/j.mpsur.2019.07.013] [Reference Citation Analysis]
227 Atti V, Turagam MK, Garg J, Velagapudi P, Patel NJ, Basir MB, Mujer MT, Rayamajhi S, Abela GS, Koerber S, Gopinnathanair R, Lakkireddy D. Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta‐analysis. J Cardiovasc Electrophysiol 2019;30:2460-72. [DOI: 10.1111/jce.14132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
228 Moia M, Squizzato A. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding. Intern Emerg Med 2019;14:1233-9. [PMID: 31446606 DOI: 10.1007/s11739-019-02177-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
229 Tao J, Oprea AD. Periprocedural Anticoagulation Management For Nonoperating Room Anesthesia Procedures: A Clinical Guide. Semin Cardiothorac Vasc Anesth 2019;23:352-68. [PMID: 31431127 DOI: 10.1177/1089253219870627] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
230 Gottenborg E, Mitsky GJ. The Management of Anticoagulation for Venous Thromboembolism in the Hospitalized Adult. J Hosp Med 2019;14:499-500. [DOI: 10.12788/jhm.3271] [Reference Citation Analysis]
231 Bikdeli B, Krumholz HM, Hines HH Jr. Minimizing recurrent venous thromboembolism. BMJ 2019;366:l4686. [PMID: 31345836 DOI: 10.1136/bmj.l4686] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
232 Rali P, Gangemi A, Moores A, Mohrien K, Moores L. Direct-Acting Oral Anticoagulants in Critically Ill Patients. Chest 2019;156:604-18. [PMID: 31251908 DOI: 10.1016/j.chest.2019.05.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
233 Sherf-Dagan S, Goldenshluger A, Azran C, Sakran N, Sinai T, Ben-Porat T. Vitamin K-what is known regarding bariatric surgery patients: a systematic review. Surg Obes Relat Dis 2019;15:1402-13. [PMID: 31353233 DOI: 10.1016/j.soard.2019.05.031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
234 Ostermann H, von Heymann C. Prothrombin complex concentrate for vitamin K antagonist reversal in acute bleeding settings: efficacy and safety. Expert Rev Hematol 2019;12:525-40. [PMID: 31159607 DOI: 10.1080/17474086.2019.1624520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
235 Maffei FHA. Future prospects for prophylactic and therapeutic management of venous thrombosis: antithrombotic substances with lower risk of hemorrhage? J Vasc Bras 2019;18:e20190036. [PMID: 31320885 DOI: 10.1590/1677-5449.190036] [Reference Citation Analysis]
236 Shet AS, Thein SL. A Growing Population of Older Adults with Sickle Cell Disease. Clin Geriatr Med 2019;35:349-67. [PMID: 31230736 DOI: 10.1016/j.cger.2019.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
237 Flynn BC, Shen L, Littlejohn JE, Shirak MO, Ivascu NS. Noteworthy Literature in 2018 for Cardiovascular Anesthesiologists and Intensivists. Semin Cardiothorac Vasc Anesth 2019;23:156-63. [PMID: 30985250 DOI: 10.1177/1089253219842659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
238 Smith MN, Deloney L, Carter C, Weant KA, Eriksson EA. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thrombolysis 2019;48:250-5. [DOI: 10.1007/s11239-019-01846-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 14.5] [Reference Citation Analysis]
239 Schünemann HJ, Santesso N, Brozek JL. Interactive Summary of Findings tables: the way to present and understand results of systematic reviews. JBI Database of Systematic Reviews and Implementation Reports 2019;17:259-60. [DOI: 10.11124/jbisrir-d-19-00059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
240 Tanzi MG. New VTE guidelines released by ASH. Pharmacy Today 2019;25:4. [DOI: 10.1016/j.ptdy.2019.01.026] [Reference Citation Analysis]
241 Chacko B, Peter JV, Subramani K. Reversal of Anticoagulants in Critical Care. Indian J Crit Care Med 2019;23:S221-5. [PMID: 31656383 DOI: 10.5005/jp-journals-10071-23257] [Reference Citation Analysis]
242 Deloughery TG. Warfarin. Hemostasis and Thrombosis 2019. [DOI: 10.1007/978-3-030-19330-0_25] [Reference Citation Analysis]
243 Damanti S, Braham S, Pasina L. Anticoagulation in frail older people. J Geriatr Cardiol 2019;16:844-6. [PMID: 31853251 DOI: 10.11909/j.issn.1671-5411.2019.11.005] [Cited by in F6Publishing: 3] [Reference Citation Analysis]